US2770569A
(en)
|
1952-08-01 |
1956-11-13 |
Hoffmann La Roche |
Analgesic compositions
|
US3493657A
(en)
*
|
1961-03-14 |
1970-02-03 |
Mozes Juda Lewenstein |
Therapeutic compositions of n-allyl-14-hydroxy - dihydronormorphinane and morphine
|
US3332950A
(en)
|
1963-03-23 |
1967-07-25 |
Endo Lab |
14-hydroxydihydronormorphinone derivatives
|
US3773955A
(en)
|
1970-08-03 |
1973-11-20 |
Bristol Myers Co |
Analgetic compositions
|
US3879555A
(en)
*
|
1970-11-16 |
1975-04-22 |
Bristol Myers Co |
Method of treating drug addicts
|
US3676557A
(en)
|
1971-03-02 |
1972-07-11 |
Endo Lab |
Long-acting narcotic antagonist formulations
|
US3965256A
(en)
|
1972-05-16 |
1976-06-22 |
Synergistics |
Slow release pharmaceutical compositions
|
US3966940A
(en)
|
1973-11-09 |
1976-06-29 |
Bristol-Myers Company |
Analgetic compositions
|
US4176186A
(en)
|
1978-07-28 |
1979-11-27 |
Boehringer Ingelheim Gmbh |
Quaternary derivatives of noroxymorphone which relieve intestinal immobility
|
US4469827A
(en)
|
1978-12-15 |
1984-09-04 |
Hospal-Sodip Sa |
Mixtures of polymers for medical use
|
US4237140A
(en)
|
1979-05-18 |
1980-12-02 |
E. I. Du Pont De Nemours And Company |
Analgesic mixture of nalbuphine and acetaminophen
|
IE49324B1
(en)
|
1979-12-19 |
1985-09-18 |
Euro Celtique Sa |
Controlled release compositions
|
US4457933A
(en)
|
1980-01-24 |
1984-07-03 |
Bristol-Myers Company |
Prevention of analgesic abuse
|
US4464378A
(en)
|
1981-04-28 |
1984-08-07 |
University Of Kentucky Research Foundation |
Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
|
JPS5862667A
(en)
|
1981-10-09 |
1983-04-14 |
Olympus Optical Co Ltd |
Electrophotographic method for plural copies
|
US4401672A
(en)
|
1981-10-13 |
1983-08-30 |
Regents Of The University Of Minnesota |
Non-addictive narcotic antitussive preparation
|
US4608376A
(en)
|
1981-10-16 |
1986-08-26 |
Carolyn McGinnis |
Opiate agonists and antagonists
|
US4987136A
(en)
*
|
1982-03-16 |
1991-01-22 |
The Rockefeller University |
Method for controlling gastrointestinal dysmotility
|
US4443428A
(en)
*
|
1982-06-21 |
1984-04-17 |
Euroceltique, S.A. |
Extended action controlled release compositions
|
US4451470A
(en)
|
1982-07-06 |
1984-05-29 |
E. I. Du Pont De Nemours And Company |
Analgesic, antagonist, and/or anorectic 14-fluoromorphinans
|
US4803208A
(en)
*
|
1982-09-30 |
1989-02-07 |
Sloan-Kettering Institute For Cancer Research |
Opiate agonists and antagonists
|
GB8332556D0
(en)
*
|
1983-12-06 |
1984-01-11 |
Reckitt & Colmann Prod Ltd |
Analgesic compositions
|
US5266574A
(en)
|
1984-04-09 |
1993-11-30 |
Ian S. Zagon |
Growth regulation and related applications of opioid antagonists
|
US5288498A
(en)
*
|
1985-05-01 |
1994-02-22 |
University Of Utah Research Foundation |
Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments
|
US4668685A
(en)
|
1984-07-05 |
1987-05-26 |
E.I. Du Pont De Nemours And Company |
Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists
|
DE3434946A1
(en)
*
|
1984-09-22 |
1986-04-03 |
Basf Ag, 6700 Ludwigshafen |
DIARYLACETYLENE, THEIR PRODUCTION AND USE
|
US4573995A
(en)
*
|
1984-10-09 |
1986-03-04 |
Alza Corporation |
Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine
|
GB8430346D0
(en)
*
|
1984-11-30 |
1985-01-09 |
Reckitt & Colmann Prod Ltd |
Analgesic compositions
|
US4806341A
(en)
*
|
1985-02-25 |
1989-02-21 |
Rutgers, The State University Of New Jersey |
Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
|
US5288497A
(en)
*
|
1985-05-01 |
1994-02-22 |
The University Of Utah |
Compositions of oral dissolvable medicaments
|
US5785989A
(en)
|
1985-05-01 |
1998-07-28 |
University Utah Research Foundation |
Compositions and methods of manufacturing of oral dissolvable medicaments
|
US5122127A
(en)
|
1985-05-01 |
1992-06-16 |
University Of Utah |
Apparatus and methods for use in administering medicaments by direct medicament contact to mucosal tissues
|
GB8514665D0
(en)
|
1985-06-11 |
1985-07-10 |
Eroceltique Sa |
Oral pharmaceutical composition
|
FR2585246A1
(en)
|
1985-07-26 |
1987-01-30 |
Cortial |
PROCESS FOR OBTAINING SOLID PHARMACEUTICAL FORMS WITH PROLONGED RELEASE
|
GB8521350D0
(en)
|
1985-08-28 |
1985-10-02 |
Euro Celtique Sa |
Analgesic composition
|
US4889860A
(en)
|
1985-09-23 |
1989-12-26 |
Nova Pharmaceutical Corporation |
Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists
|
US4760069A
(en)
|
1985-09-23 |
1988-07-26 |
Nova Pharmaceutical Corporation |
Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists
|
US4722928A
(en)
*
|
1985-12-02 |
1988-02-02 |
E. I. Du Pont De Nemours And Company |
N-oxide prodrug derivatives of 3-hydroxy morphinans and partial morphinans having improved oral bioavailability, pharmaceutical compositions, and processes
|
US4730048A
(en)
*
|
1985-12-12 |
1988-03-08 |
Regents Of The University Of Minnesota |
Gut-selective opiates
|
US4719215A
(en)
*
|
1986-03-07 |
1988-01-12 |
University Of Chicago |
Quaternary derivatives of noroxymorphone which relieve nausea and emesis
|
US4861781A
(en)
|
1986-03-07 |
1989-08-29 |
The University Of Chicago |
Quaternary derivatives of noroxymorphone which relieve nausea and emesis
|
US5316759A
(en)
|
1986-03-17 |
1994-05-31 |
Robert J. Schaap |
Agonist-antagonist combination to reduce the use of nicotine and other drugs
|
GB8613689D0
(en)
|
1986-06-05 |
1986-07-09 |
Euro Celtique Sa |
Pharmaceutical composition
|
GB8613688D0
(en)
|
1986-06-05 |
1986-07-09 |
Euro Celtique Sa |
Pharmaceutical composition
|
ATE107857T1
(en)
|
1986-06-10 |
1994-07-15 |
Euro Celtique Sa |
COMPOSITION WITH CONTROLLED RELEASE OF DIHYDROCODEINE.
|
US4785000A
(en)
|
1986-06-18 |
1988-11-15 |
The Rockefeller University |
Method of treating patients suffering from chronic pain or chronic cough
|
US4769372A
(en)
|
1986-06-18 |
1988-09-06 |
The Rockefeller University |
Method of treating patients suffering from chronic pain or chronic cough
|
US4970075A
(en)
|
1986-07-18 |
1990-11-13 |
Euroceltique, S.A. |
Controlled release bases for pharmaceuticals
|
US4861598A
(en)
|
1986-07-18 |
1989-08-29 |
Euroceltique, S.A. |
Controlled release bases for pharmaceuticals
|
US5356900A
(en)
|
1986-10-07 |
1994-10-18 |
Bernard Bihari |
Method of treating chronic herpes virus infections using an opiate receptor antagonist
|
GB8626098D0
(en)
|
1986-10-31 |
1986-12-03 |
Euro Celtique Sa |
Controlled release hydromorphone composition
|
US4806543A
(en)
*
|
1986-11-25 |
1989-02-21 |
Board Of Trustees Of The Leland Stanford Junior University |
Method and compositions for reducing neurotoxic injury
|
GB8628728D0
(en)
|
1986-12-02 |
1987-01-07 |
Euro Celtique Sa |
Spheroids
|
GB8705083D0
(en)
|
1987-03-04 |
1987-04-08 |
Euro Celtique Sa |
Spheroids
|
GB8728294D0
(en)
|
1987-12-03 |
1988-01-06 |
Reckitt & Colmann Prod Ltd |
Treatment compositions
|
US4774230A
(en)
|
1988-03-26 |
1988-09-27 |
Ivax Laboratories, Inc. |
Glucuronic acid derivatives of opioid antagonists
|
US4873076A
(en)
|
1988-04-29 |
1989-10-10 |
Baker Cummins Pharmaceuticals, Inc. |
Method of safely providing anesthesia or conscious sedation
|
GB8813064D0
(en)
*
|
1988-06-02 |
1988-07-06 |
Euro Celtique Sa |
Controlled release dosage forms having defined water content
|
US4882335A
(en)
|
1988-06-13 |
1989-11-21 |
Alko Limited |
Method for treating alcohol-drinking response
|
US5236714A
(en)
|
1988-11-01 |
1993-08-17 |
Alza Corporation |
Abusable substance dosage form having reduced abuse potential
|
CA2002492A1
(en)
|
1988-11-11 |
1990-05-11 |
Sandra T. A. Malkowska |
Pharmaceutical ion exchange resin composition
|
US5102887A
(en)
*
|
1989-02-17 |
1992-04-07 |
Arch Development Corporation |
Method for reducing emesis and nausea induced by the administration of an emesis causing agent
|
ES2083982T3
(en)
|
1989-07-14 |
1996-05-01 |
Hunter Eng Co |
REGULATION OF THE FLEXION IN A CASTING MACHINE BETWEEN ROLLERS.
|
US5096715A
(en)
*
|
1989-11-20 |
1992-03-17 |
Alko Ltd. |
Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist
|
US5075341A
(en)
|
1989-12-01 |
1991-12-24 |
The Mclean Hospital Corporation |
Treatment for cocaine abuse
|
US5086058A
(en)
*
|
1990-06-04 |
1992-02-04 |
Alko Ltd. |
Method for treating alcoholism with nalmefene
|
HU208633B
(en)
|
1991-02-04 |
1993-12-28 |
Alkaloida Vegyeszeti Gyar |
Process for production of analgetic compositions as applicable for blocking of opioid-binding spaces /2-receptors/ causing respiration depression
|
US5486362A
(en)
*
|
1991-05-07 |
1996-01-23 |
Dynagen, Inc. |
Controlled, sustained release delivery system for treating drug dependency
|
US5149538A
(en)
|
1991-06-14 |
1992-09-22 |
Warner-Lambert Company |
Misuse-resistive transdermal opioid dosage form
|
KR100221695B1
(en)
*
|
1991-08-12 |
1999-09-15 |
그린 마틴, 브라이언 쥐 테슬리 |
Pharmaceutical spheroid formulation
|
DE122004000032I2
(en)
|
1991-09-06 |
2006-02-09 |
Mcneilab Inc |
Composition containing a tramadol compound and acetaminophen, and their use
|
US5215758A
(en)
|
1991-09-11 |
1993-06-01 |
Euroceltique, S.A. |
Controlled release matrix suppository for pharmaceuticals
|
US5225440A
(en)
|
1991-09-13 |
1993-07-06 |
The United States Of America As Represented By The Department Of Health And Human Services |
Attenuation of the opioid withdrawal syndrome by inhibitors of nitric oxide synthase
|
EP0533280B2
(en)
|
1991-09-20 |
2004-12-01 |
Glaxo Group Limited |
Novel medical use for tachykinin antagonists
|
US5226331A
(en)
|
1991-10-03 |
1993-07-13 |
General Electric Company |
Apparatus and method for measuring the particle number rate and the velocity distribution of a sprayed stream
|
US5656295A
(en)
|
1991-11-27 |
1997-08-12 |
Euro-Celtique, S.A. |
Controlled release oxycodone compositions
|
US5266331A
(en)
*
|
1991-11-27 |
1993-11-30 |
Euroceltique, S.A. |
Controlled release oxycodone compositions
|
US5916540A
(en)
|
1994-10-24 |
1999-06-29 |
Glaxo Group Limited |
Aerosol formulations containing P134A and/or P227 and particulate medicament
|
US5472712A
(en)
|
1991-12-24 |
1995-12-05 |
Euroceltique, S.A. |
Controlled-release formulations coated with aqueous dispersions of ethylcellulose
|
US5681585A
(en)
|
1991-12-24 |
1997-10-28 |
Euro-Celtique, S.A. |
Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
|
US5968551A
(en)
|
1991-12-24 |
1999-10-19 |
Purdue Pharma L.P. |
Orally administrable opioid formulations having extended duration of effect
|
US5580578A
(en)
|
1992-01-27 |
1996-12-03 |
Euro-Celtique, S.A. |
Controlled release formulations coated with aqueous dispersions of acrylic polymers
|
US5286493A
(en)
*
|
1992-01-27 |
1994-02-15 |
Euroceltique, S.A. |
Stabilized controlled release formulations having acrylic polymer coating
|
US5273760A
(en)
|
1991-12-24 |
1993-12-28 |
Euroceltigue, S.A. |
Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
|
US5478577A
(en)
|
1993-11-23 |
1995-12-26 |
Euroceltique, S.A. |
Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
|
US5958459A
(en)
|
1991-12-24 |
1999-09-28 |
Purdue Pharma L.P. |
Opioid formulations having extended controlled released
|
GB9203689D0
(en)
*
|
1992-02-20 |
1992-04-08 |
Euro Celtique Sa |
Pharmaceutical composition
|
GB9204354D0
(en)
|
1992-02-28 |
1992-04-08 |
Biokine Tech Ltd |
Compounds for medicinal use
|
US5506257A
(en)
*
|
1992-03-26 |
1996-04-09 |
University Of British Columbia |
Aminocyclohexylamides for antiarrhythmic and anaesthetic uses
|
PT647137E
(en)
|
1992-06-22 |
2008-11-24 |
Univ California |
Glycine receptor antagonists and the use thereof
|
US5352680A
(en)
|
1992-07-15 |
1994-10-04 |
Regents Of The University Of Minnesota |
Delta opioid receptor antagonists to block opioid agonist tolerance and dependence
|
US5256669A
(en)
|
1992-08-07 |
1993-10-26 |
Aminotek Sciences, Inc. |
Methods and compositions for treating acute or chronic pain and drug addiction
|
US5324351A
(en)
|
1992-08-13 |
1994-06-28 |
Euroceltique |
Aqueous dispersions of zein and preparation thereof
|
US5472943A
(en)
|
1992-09-21 |
1995-12-05 |
Albert Einstein College Of Medicine Of Yeshiva University, |
Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists
|
US5512578A
(en)
*
|
1992-09-21 |
1996-04-30 |
Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University |
Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists
|
US5633259A
(en)
|
1992-09-21 |
1997-05-27 |
United Biomedical, Inc. |
Method for identification of low/non-addictive opioid analgesics and the use of said analgesics for treatment of opioid addiction
|
US20010006967A1
(en)
|
1992-09-21 |
2001-07-05 |
Stanley M. Crain |
Method of simultaneously enhancing analgesic potency and attenuating adverse side effects caused by tramadol and other bimodally-acting opioid agonists
|
US5580876A
(en)
|
1992-09-21 |
1996-12-03 |
Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University |
Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
|
US6096756A
(en)
|
1992-09-21 |
2000-08-01 |
Albert Einstein College Of Medicine Of Yeshiva University |
Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
|
US5869097A
(en)
*
|
1992-11-02 |
1999-02-09 |
Alza Corporation |
Method of therapy comprising an osmotic caplet
|
US5321012A
(en)
|
1993-01-28 |
1994-06-14 |
Virginia Commonwealth University Medical College |
Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
|
US5585348A
(en)
|
1993-02-10 |
1996-12-17 |
Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University |
Use of excitatory opioid receptor antagonists to prevent growth factor-induced hyperalgesia
|
US5512593A
(en)
*
|
1993-03-02 |
1996-04-30 |
John S. Nagle |
Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
|
US5352683A
(en)
|
1993-03-05 |
1994-10-04 |
Virginia Commonwealth University Medical College Of Virginia |
Method for the treatment of chronic pain
|
CA2115792C
(en)
*
|
1993-03-05 |
2005-11-01 |
David J. Mayer |
Method for the treatment of pain
|
IL119660A
(en)
|
1993-05-10 |
2002-09-12 |
Euro Celtique Sa |
Controlled release formulation comprising tramadol
|
US5457208A
(en)
|
1993-06-21 |
1995-10-10 |
Regents Of The University Of Minnesota |
Kappa opioid receptor antagonists
|
IL110014A
(en)
|
1993-07-01 |
1999-11-30 |
Euro Celtique Sa |
Solid controlled-release oral dosage forms of opioid analgesics
|
US5879705A
(en)
|
1993-07-27 |
1999-03-09 |
Euro-Celtique S.A. |
Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
|
US5411965A
(en)
|
1993-08-23 |
1995-05-02 |
Arizona Board Of Regents |
Use of delta opioid receptor antagonists to treat cocaine abuse
|
GB9319568D0
(en)
|
1993-09-22 |
1993-11-10 |
Euro Celtique Sa |
Pharmaceutical compositions and usages
|
US5464841A
(en)
|
1993-11-08 |
1995-11-07 |
Univ Minnesota |
Use of delta opioid receptor antagonists to treat immunoregulatory disorders
|
US5891471A
(en)
*
|
1993-11-23 |
1999-04-06 |
Euro-Celtique, S.A. |
Pharmaceutical multiparticulates
|
KR100354702B1
(en)
|
1993-11-23 |
2002-12-28 |
유로-셀티크 소시에떼 아노뉨 |
Manufacturing method and sustained release composition of pharmaceutical composition
|
US5500227A
(en)
*
|
1993-11-23 |
1996-03-19 |
Euro-Celtique, S.A. |
Immediate release tablet cores of insoluble drugs having sustained-release coating
|
US6210714B1
(en)
|
1993-11-23 |
2001-04-03 |
Euro-Celtique S.A. |
Immediate release tablet cores of acetaminophen having sustained-release coating
|
US5376662A
(en)
|
1993-12-08 |
1994-12-27 |
Ockert; David M. |
Method of attenuating nerve injury induced pain
|
US5834477A
(en)
|
1993-12-08 |
1998-11-10 |
The United States Of America As Represented By The Secretary Of The Army |
Opiate analgesic formulation with improved safety
|
US5843480A
(en)
|
1994-03-14 |
1998-12-01 |
Euro-Celtique, S.A. |
Controlled release diamorphine formulation
|
US5411745A
(en)
|
1994-05-25 |
1995-05-02 |
Euro-Celtique, S.A. |
Powder-layered morphine sulfate formulations
|
US6077533A
(en)
|
1994-05-25 |
2000-06-20 |
Purdue Pharma L.P. |
Powder-layered oral dosage forms
|
US5460826A
(en)
|
1994-06-27 |
1995-10-24 |
Alza Corporation |
Morphine therapy
|
US5616601A
(en)
*
|
1994-07-28 |
1997-04-01 |
Gd Searle & Co |
1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
|
JPH10508575A
(en)
|
1994-08-30 |
1998-08-25 |
ユニバーシティ オブ ダンディー |
Apoptosis inducer and application of the inducer in therapy
|
GB9422154D0
(en)
|
1994-11-03 |
1994-12-21 |
Euro Celtique Sa |
Pharmaceutical compositions and method of producing the same
|
US5965161A
(en)
|
1994-11-04 |
1999-10-12 |
Euro-Celtique, S.A. |
Extruded multi-particulates
|
CN1160115C
(en)
*
|
1994-12-12 |
2004-08-04 |
奥默罗斯公司 |
Irrigation solution and method for inhibition of pain, inflammation
|
GB9426102D0
(en)
*
|
1994-12-23 |
1995-02-22 |
Merck Sharp & Dohme |
Pharmacuetical compositions
|
US5552422A
(en)
|
1995-01-11 |
1996-09-03 |
Merck Frosst Canada, Inc. |
Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
|
US6299901B1
(en)
|
1995-01-13 |
2001-10-09 |
Somerset Pharmaceuticals, Inc. |
Methods and pharmaceutical compositions employing desmethylselegiline
|
US6319954B1
(en)
|
1995-01-13 |
2001-11-20 |
Somerset Pharmaceuticals, Inc. |
S-(+)-desmethylselegiline and its use in the therapeutic methods and pharmaceutical compositions
|
US5578725A
(en)
|
1995-01-30 |
1996-11-26 |
Regents Of The University Of Minnesota |
Delta opioid receptor antagonists
|
DE69603577T2
(en)
|
1995-02-10 |
1999-11-25 |
Medtronic Inc |
METHOD AND DEVICE FOR ADMINISTERING ANALGES
|
US7048906B2
(en)
*
|
1995-05-17 |
2006-05-23 |
Cedars-Sinai Medical Center |
Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
|
US6558708B1
(en)
|
1995-05-17 |
2003-05-06 |
Cedars-Sinai Medical Center |
Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
|
AU706541B2
(en)
|
1995-06-09 |
1999-06-17 |
Euro-Celtique S.A. |
Formulations and methods for providing prolonged local anesthesia
|
US5931809A
(en)
|
1995-07-14 |
1999-08-03 |
Depotech Corporation |
Epidural administration of therapeutic compounds with sustained rate of release
|
CA2182851A1
(en)
|
1995-08-15 |
1997-02-16 |
August Masaru Watanabe |
Method for treating substance abuse withdrawal
|
EP0844870B1
(en)
*
|
1995-08-17 |
2001-11-21 |
Csir |
Controlled release products
|
US5962602A
(en)
|
1995-08-18 |
1999-10-05 |
Sika Corporation Usa |
Ultra-low viscosity epoxy sealer/healer
|
GB9517883D0
(en)
|
1995-09-01 |
1995-11-01 |
Euro Celtique Sa |
Improved pharmaceutical ion exchange resin composition
|
GB9519363D0
(en)
|
1995-09-22 |
1995-11-22 |
Euro Celtique Sa |
Pharmaceutical formulation
|
US5716631A
(en)
*
|
1995-09-29 |
1998-02-10 |
Rdn Therapeutics Inc. |
Long acting narcotic analgesics and antagonists
|
US5811126A
(en)
|
1995-10-02 |
1998-09-22 |
Euro-Celtique, S.A. |
Controlled release matrix for pharmaceuticals
|
AUPN603895A0
(en)
|
1995-10-19 |
1995-11-09 |
University Of Queensland, The |
Production of analgesic synergy by co-administration of sub-analgesic doses of two strong opioids
|
AU1128297A
(en)
|
1995-12-06 |
1997-06-27 |
Eli Lilly And Company |
Composition for treating pain
|
DK0888111T3
(en)
|
1996-03-08 |
2003-09-22 |
Nycomed Danmark As |
Modified-release dosage preparation with multiple units
|
DK0914097T3
(en)
*
|
1996-03-12 |
2002-04-29 |
Alza Corp |
Composition and dosage form comprising opioid antagonist
|
US6103258A
(en)
|
1996-04-12 |
2000-08-15 |
Simon; David Lew |
Salts and bases of the 17-(Cyclopropylmethyl)-4,5 alpha-epoxy-6-Methylenemorphinan-3,14 diol molecule for optimizing dopamine homeostasis during administration of opioid analgesics
|
US20030211157A1
(en)
|
1996-05-06 |
2003-11-13 |
Simon David Lew |
Semi-sol delivery blend for water soluble molecules
|
DE19630035A1
(en)
|
1996-07-25 |
1998-01-29 |
Asta Medica Ag |
Tramadol multiple unit formulations
|
DE19651551C2
(en)
|
1996-12-11 |
2000-02-03 |
Klinge Co Chem Pharm Fab |
Opioid antagonist-containing galenic formulation
|
US6203813B1
(en)
*
|
1997-01-13 |
2001-03-20 |
Lance L. Gooberman |
Pharmaceutical delivery device and method of preparation therefor
|
GB9700878D0
(en)
|
1997-01-17 |
1997-03-05 |
Scherer Ltd R P |
Dosage forms and method for ameliorating male erectile dysfunction
|
DK1003494T3
(en)
|
1997-01-22 |
2007-07-16 |
Cornell Res Foundation Inc |
(d) -methadone, a non-opioid analgesic
|
US5968547A
(en)
|
1997-02-24 |
1999-10-19 |
Euro-Celtique, S.A. |
Method of providing sustained analgesia with buprenorphine
|
US5780479A
(en)
|
1997-04-04 |
1998-07-14 |
Regents Of The University Of Minnesota |
Use of opioid antagonists to treat impulse-control disorders
|
US5980882A
(en)
|
1997-04-16 |
1999-11-09 |
Medeva Pharmaceuticals Manufacturing |
Drug-resin complexes stabilized by chelating agents
|
US6153621A
(en)
|
1997-06-23 |
2000-11-28 |
The University Of Kentucky Research Foundation |
Combined antagonist compositions
|
ATE322892T1
(en)
|
1997-07-02 |
2006-04-15 |
Euro Celtique Sa |
STABILIZED SUSTAINED-RELEASE TRAMADOL FORMULATIONS
|
CA2301883A1
(en)
|
1997-09-11 |
1999-03-18 |
Nycomed Danmark A/S |
Modified release multiple-units compositions of non-steroid anti-inflammatory drug substances (nsaids)
|
US5972954A
(en)
*
|
1997-11-03 |
1999-10-26 |
Arch Development Corporation |
Use of methylnaltrexone and related compounds
|
JP4761093B2
(en)
|
1997-12-10 |
2011-08-31 |
シクロスポリン セラポイティクス リミテッド |
Pharmaceutical composition comprising omega-3 fatty acid oil
|
US20030059471A1
(en)
*
|
1997-12-15 |
2003-03-27 |
Compton Bruce Jon |
Oral delivery formulation
|
US6375957B1
(en)
|
1997-12-22 |
2002-04-23 |
Euro-Celtique, S.A. |
Opioid agonist/opioid antagonist/acetaminophen combinations
|
US6228863B1
(en)
|
1997-12-22 |
2001-05-08 |
Euro-Celtique S.A. |
Method of preventing abuse of opioid dosage forms
|
US5985856A
(en)
|
1997-12-31 |
1999-11-16 |
University Of Kansas |
Water soluble prodrugs of secondary and tertiary amine containing drugs and methods of making thereof
|
US6093743A
(en)
|
1998-06-23 |
2000-07-25 |
Medinox Inc. |
Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
|
CA2335277A1
(en)
|
1998-07-16 |
2000-01-27 |
Memorial Sloan-Kettering Cancer Center |
Multiple splice variants of the mu-opioid receptor gene
|
DK1109534T3
(en)
*
|
1998-09-10 |
2003-06-10 |
Nycomed Danmark As |
Pharmaceuticals with quick release of the active substance
|
US20030211136A1
(en)
|
1998-09-25 |
2003-11-13 |
Neema Kulkarni |
Fast dissolving orally consumable films containing a sweetener
|
US7067144B2
(en)
|
1998-10-20 |
2006-06-27 |
Omeros Corporation |
Compositions and methods for systemic inhibition of cartilage degradation
|
US6194382B1
(en)
|
1999-03-03 |
2001-02-27 |
Albert Einstein College Of Medicine Of Yeshiva University |
Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists
|
US6765010B2
(en)
|
1999-05-06 |
2004-07-20 |
Pain Therapeutics, Inc. |
Compositions and methods for enhancing analgesic potency of tramadol and attenuating its adverse side effects
|
US6677332B1
(en)
|
1999-05-25 |
2004-01-13 |
Sepracor, Inc. |
Heterocyclic analgesic compounds and methods of use thereof
|
US7361666B2
(en)
*
|
1999-05-25 |
2008-04-22 |
Sepracor, Inc. |
Heterocyclic analgesic compounds and methods of use thereof
|
US6635661B2
(en)
|
2000-05-25 |
2003-10-21 |
Sepracor Inc. |
Heterocyclic analgesic compounds and methods of use thereof
|
US20030235595A1
(en)
|
1999-06-30 |
2003-12-25 |
Feng-Jing Chen |
Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent
|
US20030118641A1
(en)
|
2000-07-27 |
2003-06-26 |
Roxane Laboratories, Inc. |
Abuse-resistant sustained-release opioid formulation
|
US6231594B1
(en)
|
1999-08-11 |
2001-05-15 |
Radiant Medical, Inc. |
Method of controlling body temperature while reducing shivering
|
US6264981B1
(en)
|
1999-10-27 |
2001-07-24 |
Anesta Corporation |
Oral transmucosal drug dosage using solid solution
|
PT1225897E
(en)
|
1999-11-01 |
2005-01-31 |
John Rhodes |
COMPOSITION FOR THE TREATMENT OF OBSTIPACY AND IRRITAVEL INTESTINAL SYNDROME
|
DE19960154A1
(en)
*
|
1999-12-14 |
2001-07-12 |
Lohmann Therapie Syst Lts |
Flat pharmaceutical preparation for transmucosal administration of oxycodone or a comparable active ingredient in the oral cavity, for use in pain therapy and addiction therapy
|
US6491949B2
(en)
|
2000-01-14 |
2002-12-10 |
Osmotica Corp. |
Osmotic device within an osmotic device
|
US6753011B2
(en)
|
2000-01-14 |
2004-06-22 |
Osmotica Corp |
Combined diffusion/osmotic pumping drug delivery system
|
US20030144271A1
(en)
|
2000-01-22 |
2003-07-31 |
Albert Shulman |
Methods for the treatment of substance abuse
|
US6716449B2
(en)
|
2000-02-08 |
2004-04-06 |
Euro-Celtique S.A. |
Controlled-release compositions containing opioid agonist and antagonist
|
US6433196B1
(en)
|
2000-02-17 |
2002-08-13 |
Sumika Fine Chemicals Co., Ltd. |
Production method of citalopram, intermediate therefor and production method of the intermediate
|
JP2001261575A
(en)
|
2000-03-13 |
2001-09-26 |
General Hospital Corp |
Method for regulating vasoconstriction and its composition
|
AU2001239896A1
(en)
*
|
2000-03-16 |
2001-10-03 |
Sepracor, Inc. |
Peptidomimetic ligands for cellular receptors and ion channels
|
US20010036943A1
(en)
|
2000-04-07 |
2001-11-01 |
Coe Jotham W. |
Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
|
US20040024004A1
(en)
*
|
2001-05-04 |
2004-02-05 |
Sherman Barry M. |
Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists
|
US6762202B2
(en)
|
2000-05-09 |
2004-07-13 |
Nitromed, Inc. |
Infrared thermography and methods of use
|
AU2001216218A1
(en)
|
2000-05-25 |
2001-12-11 |
Sepracor, Inc. |
Heterocyclic analgesic compounds and method of use thereof
|
WO2001091553A1
(en)
*
|
2000-05-26 |
2001-12-06 |
Demegen, Inc. |
Composite wafer for controlled drug delivery
|
US6690888B1
(en)
*
|
2000-07-21 |
2004-02-10 |
Texas Instruments Incorporated |
Method for establishing and maintaining optical, open-air communications link
|
US20020099013A1
(en)
|
2000-11-14 |
2002-07-25 |
Thomas Piccariello |
Active agent delivery systems and methods for protecting and administering active agents
|
US20020119192A1
(en)
|
2000-09-22 |
2002-08-29 |
Vishwanathan Narayanan Badri |
Controlled release formulations for oral administration
|
GB0026137D0
(en)
|
2000-10-25 |
2000-12-13 |
Euro Celtique Sa |
Transdermal dosage form
|
US6569449B1
(en)
|
2000-11-13 |
2003-05-27 |
University Of Kentucky Research Foundation |
Transdermal delivery of opioid antagonist prodrugs
|
US20040087561A1
(en)
|
2000-11-17 |
2004-05-06 |
Gonzalez Maria Isabel |
Treatment of sexual dysfunction
|
US6476046B1
(en)
|
2000-12-04 |
2002-11-05 |
Sepracor, Inc. |
Diazabicyclo[4.3.0]nonanes, and methods of use thereof
|
WO2002045713A2
(en)
|
2000-12-04 |
2002-06-13 |
Sepracor, Inc. |
Orally-bioavailable formulations of fentanyl and congeners thereof
|
US6974824B2
(en)
|
2001-01-08 |
2005-12-13 |
Research Triangle Institute |
Kappa opioid receptor ligands
|
US6559159B2
(en)
|
2001-02-01 |
2003-05-06 |
Research Triangle Institute |
Kappa opioid receptor ligands
|
US20020160043A1
(en)
|
2001-02-27 |
2002-10-31 |
Dennis Coleman |
Compositions and method of manufacture for oral dissolvable dosage forms
|
AU2002305066B8
(en)
|
2001-03-23 |
2008-04-17 |
Albert Einstein College Of Medicine Of Yeshiva University |
Methods for increasing analgesic potency and attenuating adverse excitatory effects of bimodally-acting opioid agonists by inhibiting GM1-ganglioside
|
EP2266718B1
(en)
|
2001-04-23 |
2016-06-22 |
Euro-Celtique S.A. |
Disposal system for transdermal dosage form
|
US20030065002A1
(en)
*
|
2001-05-11 |
2003-04-03 |
Endo Pharmaceuticals, Inc. |
Abuse-resistant controlled-release opioid dosage form
|
DE60216078T2
(en)
*
|
2001-05-11 |
2007-07-05 |
Endo Pharmaceuticals Inc. |
OPIOID CONTAINING ARZNEIFORM AGAINST MISUSE
|
WO2002094172A2
(en)
|
2001-05-22 |
2002-11-28 |
Euro-Celtique |
Compartmentalized dosage form
|
US7458374B2
(en)
|
2002-05-13 |
2008-12-02 |
Alexza Pharmaceuticals, Inc. |
Method and apparatus for vaporizing a compound
|
US20040156903A1
(en)
|
2002-05-22 |
2004-08-12 |
Abrams Andrew L.. |
Metering and packaging of controlled release medication
|
US6858580B2
(en)
*
|
2001-06-04 |
2005-02-22 |
Nobex Corporation |
Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
CA2449175A1
(en)
*
|
2001-06-05 |
2002-12-12 |
University Of Chicago |
Use of methylnaltrexone to treat immune suppression
|
US7968119B2
(en)
*
|
2001-06-26 |
2011-06-28 |
Farrell John J |
Tamper-proof narcotic delivery system
|
US20030003113A1
(en)
*
|
2001-06-29 |
2003-01-02 |
Lewandowski Leon J. |
Individualized addiction cessation therapy
|
US7034059B2
(en)
|
2001-07-02 |
2006-04-25 |
Sepracor Inc. |
Methods of using norfluoxetine
|
US20030055075A1
(en)
*
|
2001-07-13 |
2003-03-20 |
Rubsamen Reid M. |
Programmable controlled release injectable opioid formulation
|
JP4256259B2
(en)
*
|
2001-07-18 |
2009-04-22 |
ユーロ−セルティーク エス.エイ. |
Pharmaceutical formulation of oxycodone and naloxone
|
WO2003009805A2
(en)
|
2001-07-23 |
2003-02-06 |
Brigham And Women's Hospital, Inc. |
Analgesic methods using endothelin receptor ligands
|
US20030157168A1
(en)
|
2001-08-06 |
2003-08-21 |
Christopher Breder |
Sequestered antagonist formulations
|
US20030044458A1
(en)
*
|
2001-08-06 |
2003-03-06 |
Curtis Wright |
Oral dosage form comprising a therapeutic agent and an adverse-effect agent
|
US7332182B2
(en)
*
|
2001-08-06 |
2008-02-19 |
Purdue Pharma L.P. |
Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
|
AU2002323032B2
(en)
*
|
2001-08-06 |
2005-02-24 |
Euro-Celtique S.A. |
Opioid agonist formulations with releasable and sequestered antagonist
|
US7842307B2
(en)
*
|
2001-08-06 |
2010-11-30 |
Purdue Pharma L.P. |
Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
|
BR0212019A
(en)
*
|
2001-08-06 |
2005-08-09 |
Euro Celtique Sa |
Dosage forms, methods for treating pain, methods of preparing a dosage form and methods for preventing abuse of a dosage form.
|
US7157103B2
(en)
*
|
2001-08-06 |
2007-01-02 |
Euro-Celtique S.A. |
Pharmaceutical formulation containing irritant
|
US7141250B2
(en)
*
|
2001-08-06 |
2006-11-28 |
Euro-Celtique S.A. |
Pharmaceutical formulation containing bittering agent
|
US20030068375A1
(en)
*
|
2001-08-06 |
2003-04-10 |
Curtis Wright |
Pharmaceutical formulation containing gelling agent
|
US7144587B2
(en)
|
2001-08-06 |
2006-12-05 |
Euro-Celtique S.A. |
Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent
|
US20030049317A1
(en)
*
|
2001-08-30 |
2003-03-13 |
Lindsay David R. |
Method and composition for reducing the danger and preventing the abuse of controlled release pharmaceutical formulations
|
DE10142996A1
(en)
*
|
2001-09-01 |
2003-03-27 |
Paz Arzneimittelentwicklung |
Use of active ingredients with mu-opioid receptor agonistic effect as a combination drug for cancer treatment
|
US20030054030A1
(en)
*
|
2001-09-13 |
2003-03-20 |
Gary Gordon |
Method and compositions for the treatment of pruritus
|
SI1436012T1
(en)
|
2001-10-18 |
2018-03-30 |
Nektar Therapeutics |
Polymer conjugates of opioid antagonists
|
US20030082225A1
(en)
|
2001-10-19 |
2003-05-01 |
Mason Paul Arthur |
Sterile, breathable patch for treating wound pain
|
US6458795B1
(en)
|
2001-11-15 |
2002-10-01 |
University Of Florida |
Method and composition for treatment of irritable bowel disease
|
US7204997B2
(en)
|
2002-01-29 |
2007-04-17 |
Supratek Pharma Inc. |
Responsive microgel and methods related thereto
|
US20030180357A1
(en)
|
2002-02-07 |
2003-09-25 |
Martino Alice C. |
Pharmaceutical tablet
|
WO2003066029A2
(en)
|
2002-02-07 |
2003-08-14 |
Pharmacia Corporation |
Pharmaceutical dosage form for mucosal delivery
|
WO2003070175A2
(en)
|
2002-02-15 |
2003-08-28 |
Howard Brooks-Korn |
Use of opioid compound to treat a neurologic or neurogenic disorder
|
ES2500117T3
(en)
*
|
2002-02-22 |
2014-09-30 |
Shire Llc |
Novel sustained release pharmaceutical compounds to prevent the abuse of controlled substances
|
JP2005526079A
(en)
|
2002-03-15 |
2005-09-02 |
サイプレス バイオサイエンス, インコーポレイテッド |
NE and 5-HT reuptake inhibitors for treating visceral pain syndrome
|
AU2003220551A1
(en)
|
2002-03-26 |
2003-10-13 |
Euro-Celtique S.A. |
Sustained-release gel coated compositions
|
US7422568B2
(en)
|
2002-04-01 |
2008-09-09 |
The Johns Hopkins University |
Device, systems and methods for localized heating of a vessel and/or in combination with MR/NMR imaging of the vessel and surrounding tissue
|
US20030191147A1
(en)
|
2002-04-09 |
2003-10-09 |
Barry Sherman |
Opioid antagonist compositions and dosage forms
|
US20030194420A1
(en)
|
2002-04-11 |
2003-10-16 |
Richard Holl |
Process for loading a drug delivery device
|
US20050106249A1
(en)
|
2002-04-29 |
2005-05-19 |
Stephen Hwang |
Once-a-day, oral, controlled-release, oxycodone dosage forms
|
US6960346B2
(en)
|
2002-05-09 |
2005-11-01 |
University Of Tennessee Research Foundation |
Vehicles for delivery of biologically active substances
|
PT1513532E
(en)
*
|
2002-06-10 |
2007-05-31 |
Euro Celtique Sa |
Disposal systems of transdermal delivery devices to prevent misuse of the active agents contained therein
|
AR039744A1
(en)
|
2002-06-26 |
2005-03-09 |
Alza Corp |
METHODS AND DOSAGE FORMS TO INCREASE THE SOLUBILITY OF PHARMACOS COMPOSITIONS FOR CONTROLLED ADMINISTRATION
|
US20040010781A1
(en)
*
|
2002-07-12 |
2004-01-15 |
Maly John Warren |
Parameter parsing system
|
NZ537543A
(en)
|
2002-07-29 |
2007-08-31 |
Alza Corp |
Formulations and high dose osmotic dosage forms for controlled delivery of topiramate
|
WO2004017941A2
(en)
|
2002-08-20 |
2004-03-04 |
Euro-Celtique, S.A. |
Transdermal dosage form comprising an active agent and a salt and free-baseform of an antagonist
|
AU2003272601B2
(en)
*
|
2002-09-20 |
2009-05-07 |
Alpharma Pharmaceuticals, Llc |
Sustained-release opioid formulations and methods of use
|
AU2003270778B2
(en)
|
2002-09-20 |
2009-10-08 |
Alpharma Pharmaceuticals, Llc |
Sequestering subunit and related compositions and methods
|
EP1543010B1
(en)
|
2002-09-25 |
2007-04-25 |
Euro-Celtique S.A. |
N-substituted hydromorphones and the use thereof
|
US20040062778A1
(en)
*
|
2002-09-26 |
2004-04-01 |
Adi Shefer |
Surface dissolution and/or bulk erosion controlled release compositions and devices
|
US20040156826A1
(en)
|
2002-09-27 |
2004-08-12 |
Fernando Dangond |
Treatment of patients with multiple sclerosis based on gene expression changes in central nervous system tissues
|
EP1556001A2
(en)
|
2002-10-31 |
2005-07-27 |
UMD, Inc. |
Therapeutic compositions for drug delivery to and through covering epithelia
|
US20040110781A1
(en)
|
2002-12-05 |
2004-06-10 |
Harmon Troy M. |
Pharmaceutical compositions containing indistinguishable drug components
|
US7670627B2
(en)
|
2002-12-09 |
2010-03-02 |
Salvona Ip Llc |
pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
|
AU2003296954A1
(en)
|
2002-12-13 |
2004-07-09 |
The Regents Of The University Of California |
Analgesic combination comprising nalbuphine
|
US20040142958A1
(en)
|
2002-12-13 |
2004-07-22 |
Neurogen Corporation |
Combination therapy for the treatment of pain
|
JP4865330B2
(en)
|
2002-12-13 |
2012-02-01 |
デュレクト コーポレーション |
Oral drug delivery system
|
US20040115287A1
(en)
|
2002-12-17 |
2004-06-17 |
Lipocine, Inc. |
Hydrophobic active agent compositions and methods
|
EP1572164A2
(en)
|
2002-12-18 |
2005-09-14 |
Pain Therapeutics, Inc. |
Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
|
US6979689B2
(en)
|
2002-12-20 |
2005-12-27 |
Pediamed Pharmaceuticals, Inc. |
Compositions and methods for treating upper respiratory congestion
|
US7524515B2
(en)
|
2003-01-10 |
2009-04-28 |
Mutual Pharmaceuticals, Inc. |
Pharmaceutical safety dosage forms
|
US20040192715A1
(en)
|
2003-02-05 |
2004-09-30 |
Mark Chasin |
Methods of administering opioid antagonists and compositions thereof
|
ATE454169T1
(en)
|
2003-03-13 |
2010-01-15 |
Controlled Chemicals Inc |
OXYCODONE CONJUGATES WITH LOWER ABUSE POTENTIAL AND EXTENDED DURATION
|
MXPA05010197A
(en)
|
2003-03-26 |
2005-11-08 |
Procter & Gamble |
Rapidly dissolving edible film compositions with improved film strength and stability.
|
EP1605905A1
(en)
|
2003-03-26 |
2005-12-21 |
The Procter & Gamble Company |
Rapidly dissolving edible film compositions with cellulose film forming polymers
|
CA2521420A1
(en)
|
2003-04-08 |
2004-10-28 |
Progenics Pharmaceuticals, Inc. |
Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist
|
US20040266806A1
(en)
|
2003-04-08 |
2004-12-30 |
Sanghvi Suketu P. |
Pharmaceutical formulation
|
MXPA05010819A
(en)
*
|
2003-04-08 |
2006-03-30 |
Progenics Pharm Inc |
The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome.
|
US20040202717A1
(en)
|
2003-04-08 |
2004-10-14 |
Mehta Atul M. |
Abuse-resistant oral dosage forms and method of use thereof
|
EP1613324A2
(en)
*
|
2003-04-14 |
2006-01-11 |
Pain Therapeutics, Inc. |
Methods for the treatment of pain comprising opioid antagonists
|
US20040209850A1
(en)
|
2003-04-15 |
2004-10-21 |
Theraquest Biosciences, Llc |
Methods of treating pain and compositions for use therefor
|
MY135852A
(en)
|
2003-04-21 |
2008-07-31 |
Euro Celtique Sa |
Pharmaceutical products
|
US20040213828A1
(en)
|
2003-04-23 |
2004-10-28 |
Smith David J. |
Pain relief lollipop compositions and methods
|
EP2316440A1
(en)
*
|
2003-04-30 |
2011-05-04 |
Purdue Pharma L.P. |
Transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer and one fluid communication between the surface of the active agent and the adverse agent
|
US8906413B2
(en)
|
2003-05-12 |
2014-12-09 |
Supernus Pharmaceuticals, Inc. |
Drug formulations having reduced abuse potential
|
US8029822B2
(en)
*
|
2003-05-22 |
2011-10-04 |
Osmotica Kereskedelmi és Seolgáltató KFT |
Rupturing controlled release device having a preformed passageway
|
DE10336400A1
(en)
*
|
2003-08-06 |
2005-03-24 |
Grünenthal GmbH |
Anti-abuse dosage form
|
US20050042281A1
(en)
*
|
2003-08-21 |
2005-02-24 |
Singh Nikhilesh N. |
Compositions for delivering therapeutic agents across the oral mucosa
|
CA2541371C
(en)
*
|
2003-10-03 |
2014-12-16 |
Atul M. Mehta |
Extended release formulations of opioids and method of use thereof
|